当前位置: 首页 >> 检索结果
41. Genetic Risk of Primary Aldosteronism and Its Contribution to Hypertension: A Cross-Ancestry Meta-Analysis of Genome-Wide Association Studies.
作者: Tatsuhiko Naito.;Kosuke Inoue.;Kyuto Sonehara.;Ryuta Baba.;Takaya Kodama.;Yu Otagaki.;Akira Okada.;Kiyotaka Itcho.;Kazuhiro Kobuke.;Shinji Kishimoto.;Kenichi Yamamoto.; .;Takayuki Morisaki.;Yukihito Higashi.;Nobuyuki Hinata.;Koji Arihiro.;Noboru Hattori.;Yukinori Okada.;Kenji Oki.
来源: Circulation. 2023年147卷14期1097-1109页
Hypertension imposes substantial health and economic burden worldwide. Primary aldosteronism (PA) is one of the most common causes of secondary hypertension, causing cardiovascular events at higher risk compared with essential hypertension. However, the germline genetic contribution to the susceptibility of PA has not been well elucidated.
42. Optimal Hemostatic Band Duration After Transradial Angiography or Intervention: Insights From a Mixed Treatment Comparison Meta-Analysis of Randomized Trials.
作者: Muhammad Haisum Maqsood.;Samir Pancholy.;Kristin A Tuozzo.;Nicole Moskowitz.;Sunil V Rao.;Sripal Bangalore.
来源: Circ Cardiovasc Interv. 2023年16卷2期e012781页
The optimal duration of hemostatic compression post transradial access is controversial. Longer duration increases the risk of radial artery occlusion (RAO) while shorter duration increases the risk of access site bleeding or hematoma. As such, a target of 2 hours is typically used. Whether a shorter or longer duration is better is not known.
43. Sex Differences in 10-Year Outcomes After Percutaneous Coronary Intervention With Drug-Eluting Stents: Insights From the DECADE Cooperation.
作者: J J Coughlan.;Lorenz Räber.;Salvatore Brugaletta.;Sebastian Kufner.;Michael Maeng.;Lisette Okkels Jensen.;Luis Ortega-Paz.;Sarah Bär.;Karl-Ludwig Laugwitz.;Morten Madsen.;Dik Heg.;Alp Aytekin.;Stephan Windecker.;Kevin Kris Warnakula Olesen.;Manel Sabaté.;Adnan Kastrati.;Salvatore Cassese.
来源: Circulation. 2023年147卷7期575-585页
Although some studies have investigated sex-related outcomes up to 5 years after percutaneous coronary intervention (PCI), analyses at longer follow-up (ie, to 10 years) in large cohorts treated exclusively with drug-eluting stent (DES) platforms are lacking. Therefore, this study aimed to define whether sex-related differences in long-term outcomes after PCI persist both in the DES era and at longer-term follow-up.
44. Prospective Association of Daily Steps With Cardiovascular Disease: A Harmonized Meta-Analysis.
作者: Amanda E Paluch.;Shivangi Bajpai.;Marcel Ballin.;David R Bassett.;Thomas W Buford.;Mercedes R Carnethon.;Ariel Chernofsky.;Erin E Dooley.;Ulf Ekelund.;Kelly R Evenson.;Deborah A Galuska.;Barbara J Jefferis.;Lingsong Kong.;William E Kraus.;Martin G Larson.;I-Min Lee.;Charles E Matthews.;Robert L Newton.;Anna Nordström.;Peter Nordström.;Priya Palta.;Alpa V Patel.;Kelley Pettee Gabriel.;Carl F Pieper.;Lisa Pompeii.;Erika Rees-Punia.;Nicole L Spartano.;Ramachandran S Vasan.;Peter H Whincup.;Shengping Yang.;Janet E Fulton.; .
来源: Circulation. 2023年147卷2期122-131页
Taking fewer than the widely promoted "10 000 steps per day" has recently been associated with lower risk of all-cause mortality. The relationship of steps and cardiovascular disease (CVD) risk remains poorly described. A meta-analysis examining the dose-response relationship between steps per day and CVD can help inform clinical and public health guidelines.
45. Response by Zhao et al to Letter Regarding Article, "Associations of Dietary Cholesterol, Serum Cholesterol, and Egg Consumption With Overall and Cause-Specific Mortality: Systematic Review and Updated Meta-Analysis".46. Reduced Mortality With Antiplatelet Therapy Deescalation After Percutaneous Coronary Intervention in Acute Coronary Syndromes: A Meta-Analysis.
作者: Tullio Palmerini.;Antonio Giulio Bruno.;Mauro Gasparini.;Giulia Rizzello.;Hyo-Soo Kim.;Jeehoon Kang.;Kyung-Woo Park.;Joo-Yong Hahn.;Young Bin Song.;Hyeon-Cheol Gwon.;Eun Ho Choo.;Mahn-Won Park.;Chan Joon Kim.;Kiyuk Chang.;Thomas Cuisset.;Nevio Taglieri.;Byeong-Keuk Kim.;Yangsoo Jang.;Elena Nardi.;Francesco Saia.;Matheusz Orzalkiewicz.;Francesco Chietera.;Gabriele Ghetti.;Nazzareno Galiè.;Gregg W Stone.
来源: Circ Cardiovasc Interv. 2022年15卷11期906-914页
Antiplatelet therapy deescalation has been suggested as an alternative to standard treatment with potent dual antiplatelet therapy (DAPT) for 1 year in low bleeding risk patients with acute coronary syndromes undergoing percutaneous coronary intervention to mitigate the increased risk of bleeding. Whether this strategy preserves the ischemic and survival benefits of potent DAPT is uncertain.
47. Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
作者: Eloisa Colin-Ramirez.;Nariman Sepehrvand.;Sarah Rathwell.;Heather Ross.;Jorge Escobedo.;Peter Macdonald.;Richard Troughton.;Clara Saldarriaga.;Fernando Lanas.;Robert Doughty.;Finlay A McAlister.;Justin A Ezekowitz.
来源: Circ Heart Fail. 2023年16卷1期e009879页
Sodium restriction is a nonpharmacologic treatment suggested by practice guidelines for the management of patients with heart failure (HF). In this study, we synthesized the data from randomized controlled trials (RCTs) evaluating the effects of sodium restriction on clinical outcomes in patients with HF.
48. Pathway-Specific Polygenic Risk Scores Identify Obstructive Sleep Apnea-Related Pathways Differentially Moderating Genetic Susceptibility to Coronary Artery Disease.
作者: Matthew O Goodman.;Brian E Cade.;Neomi A Shah.;Tianyi Huang.;Hassan S Dashti.;Richa Saxena.;Martin K Rutter.;Peter Libby.;Tamar Sofer.;Susan Redline.
来源: Circ Genom Precis Med. 2022年15卷5期e003535页
Obstructive sleep apnea (OSA) and its features, such as chronic intermittent hypoxia, may differentially affect specific molecular pathways and processes in the pathogenesis of coronary artery disease (CAD) and influence the subsequent risk and severity of CAD events. In particular, competing adverse (eg, inflammatory) and protective (eg, increased coronary collateral blood flow) mechanisms may operate, but remain poorly understood. We hypothesize that common genetic variation in selected molecular pathways influences the likelihood of CAD events differently in individuals with and without OSA, in a pathway-dependent manner.
49. Direct Oral Anticoagulants Versus Antiplatelet Therapy After Transcatheter Aortic Valve Replacement: A Meta-Analysis of Randomized Trials.
作者: Ayman Elbadawi.;Alexander T Dang.;Ramy Sedhom.;Mohamed Hamed.;Mennaallah Eid.;Harsh Golwala.;Sachin S Goel.;Mamas A Mamas.;Islam Y Elgendy.
来源: Circ Cardiovasc Interv. 2022年15卷9期e012194页 50. Effects on Mortality and Major Bleeding of Radial Versus Femoral Artery Access for Coronary Angiography or Percutaneous Coronary Intervention: Meta-Analysis of Individual Patient Data From 7 Multicenter Randomized Clinical Trials.
作者: Giuseppe Gargiulo.;Daniele Giacoppo.;Sanjit S Jolly.;John Cairns.;Michel Le May.;Ivo Bernat.;Enrico Romagnoli.;Sunil V Rao.;Maarten A H van Leeuwen.;Shamir R Mehta.;Olivier F Bertrand.;George A Wells.;Thomas A Meijers.;George C M Siontis.;Giovanni Esposito.;Stephan Windecker.;Peter Jüni.;Marco Valgimigli.; .
来源: Circulation. 2022年146卷18期1329-1343页
In some randomized clinical trials, transradial access (TRA) compared with transfemoral access (TFA) was associated with lower mortality in patients with coronary artery disease undergoing invasive management. We analyzed the effects of TRA versus TFA across multicenter randomized clinical trials and whether these associations are modified by patient or procedural characteristics.
51. Comparison of Unguided De-Escalation Versus Guided Selection of Dual Antiplatelet Therapy After Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis.
作者: Toshiki Kuno.;Tomohiro Fujisaki.;Satoshi Shoji.;Yuki Sahashi.;Yusuke Tsugawa.;Masao Iwagami.;Hisato Takagi.;Alexandros Briasoulis.;Pierre Deharo.;Thomas Cuisset.;Azeem Latib.;Shun Kohsaka.;Deepak L Bhatt.
来源: Circ Cardiovasc Interv. 2022年15卷8期e011990页
The benefit of dual antiplatelet therapy (DAPT) for reducing ischemic events is greatest in the early period of acute coronary syndrome, and recent randomized controlled trials have investigated the unguided de-escalation strategy of changing potent P2Y12 inhibitors to less potent or reduced-dose P2Y12 inhibitors 1 month after acute coronary syndrome. However, it remains unclear which strategy is more effective and safer: the uniform unguided de-escalation strategy versus the personalized guided selection of DAPT with genotype or platelet function tests.
52. Assessment of Clinical Worsening End Points as a Surrogate for Mortality in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
作者: Élodie Tremblay.;Camille Gosselin.;Vicky Mai.;Annie C Lajoie.;Roubi Kilo.;Jason Weatherald.;Yves Lacasse.;Sebastien Bonnet.;Jean-Christophe Lega.;Steeve Provencher.
来源: Circulation. 2022年146卷8期597-612页
Clinical worsening (CW) is a composite end point commonly used in pulmonary arterial hypertension (PAH) trials. We aimed to assess the trial-level surrogacy of CW for mortality in PAH trials, and whether the various CW components were similar in terms of frequency of occurrence, treatment-related relative risk (RR) reduction, and importance to patients.
53. Cost-Effectiveness of Percutaneous Coronary Intervention Versus Bypass Surgery for Patients With Left Main Disease: Results From the EXCEL Trial.
作者: Elizabeth A Magnuson.;Khaja Chinnakondepalli.;Katherine Vilain.;Patrick W Serruys.;Joseph F Sabik.;A Pieter Kappetein.;Gregg W Stone.;David J Cohen.; .
来源: Circ Cardiovasc Interv. 2022年15卷7期e011981页
The EXCEL trial (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) demonstrated in patients with left main coronary artery disease, no significant difference between coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI) with everolimus-eluting stents for the composite end point of death, stroke, or myocardial infarction at 5 years. However, all-cause mortality at 5 years was higher with PCI. Long-term cost-effectiveness of these 2 strategies has heretofore not been evaluated.
54. Arrhythmogenic Right Ventricular Cardiomyopathy Prevalence and Arrhythmic Outcomes in At-Risk Family Members: A Systematic Review and Meta-Analysis.
作者: Apurva Sharma.;Laurens P Bosman.;Crystal Tichnell.;Julie Nanavati.;Brittney Murray.;Bareng A S Nonyane.;Harikrishna Tandri.;Hugh Calkins.;Cynthia A James.
来源: Circ Genom Precis Med. 2022年15卷3期e003530页
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a complex cardiomyopathy with autosomal dominant inheritance and age-related incomplete penetrance, characterized by a high risk of sudden cardiac death. Recent professional consensus guidelines recommend clinical cardiac lifelong serial screening for at-risk family members refined only by age, but family genotype might influence necessary screening. Although numerous studies report prevalence of disease and arrhythmia in family members and explore predictors of penetrance and arrhythmic risk, a systematic review consolidating this evidence is lacking.
55. Response by Zhang et al Regarding Article "Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis".
作者: Xin-Lin Zhang.;Hong-Wei Wang.;Biao Xu.;Wei Xu.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷5期e009065页 56. Letter by de Vries et al Regarding Article "Off-Label Under- and Overdosing of Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Meta-Analysis".
作者: Tim A C de Vries.;Jack Hirsh.;Noel C Chan.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷5期e008982页 57. Comparative Efficacy of 5 Exercise Types on Cardiometabolic Health in Overweight and Obese Adults: A Systematic Review and Network Meta-Analysis of 81 Randomized Controlled Trials.
作者: Alexios Batrakoulis.;Athanasios Z Jamurtas.;Georgios S Metsios.;Konstantinos Perivoliotis.;Gary Liguori.;Yuri Feito.;Deborah Riebe.;Walter R Thompson.;Theodore J Angelopoulos.;Peter Krustrup.;Magni Mohr.;Dimitrios Draganidis.;Athanasios Poulios.;Ioannis G Fatouros.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷6期e008243页
Although regular exercise is recommended for preventing and treating overweight/obesity, the most effective exercise type for improving cardiometabolic health in individuals with overweight/obesity remains largely undecided. This network meta-analysis aimed to evaluate and rank the comparative efficacy of 5 exercise modalities on cardiometabolic health measures in individuals with overweight/obesity.
58. Compounding Benefits of Cholesterol-Lowering Therapy for the Reduction of Major Cardiovascular Events: Systematic Review and Meta-Analysis.
作者: Nelson Wang.;Mark Woodward.;Mark D Huffman.;Anthony Rodgers.
来源: Circ Cardiovasc Qual Outcomes. 2022年15卷6期e008552页
Mendelian randomization studies use genetic variants as natural experiments to provide evidence about causal relations between modifiable risk factors and disease. Recent Mendelian randomization studies suggest each mmol/L reduction in low-density lipoprotein cholesterol (LDL-C) sustained over a lifetime can reduce the risk of cardiovascular disease by more than half. However, these findings have not been replicated in randomized clinical trials, and the effect of treatment duration on the magnitude of risk reduction remains uncertain. The aim of this article was to evaluate the relationship between lipid-lowering drug exposure time and relative risk reduction of major cardiovascular events in randomized clinical trials.
59. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
作者: Brendon L Neuen.;Megumi Oshima.;Rajiv Agarwal.;Clare Arnott.;David Z Cherney.;Robert Edwards.;Anna Maria Langkilde.;Kenneth W Mahaffey.;Darren K McGuire.;Bruce Neal.;Vlado Perkovic.;Annpey Pong.;Marc S Sabatine.;Itamar Raz.;Tadashi Toyama.;Christoph Wanner.;David C Wheeler.;Stephen D Wiviott.;Bernard Zinman.;Hiddo J L Heerspink.
来源: Circulation. 2022年145卷19期1460-1470页
Hyperkalemia increases risk of cardiac arrhythmias and death and limits the use of renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor antagonists, which improve clinical outcomes in people with chronic kidney disease or systolic heart failure. Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of cardiorenal events in people with type 2 diabetes at high cardiovascular risk or with chronic kidney disease. However, their effect on hyperkalemia has not been systematically evaluated.
60. Genetic Landscape of the ACE2 Coronavirus Receptor.
作者: Zhijian Yang.;Erin Macdonald-Dunlop.;Jiantao Chen.;Ranran Zhai.;Ting Li.;Anne Richmond.;Lucija Klarić.;Nicola Pirastu.;Zheng Ning.;Chenqing Zheng.;Yipeng Wang.;Tingting Huang.;Yazhou He.;Huiming Guo.;Kejun Ying.;Stefan Gustafsson.;Bram Prins.;Anna Ramisch.;Emmanouil T Dermitzakis.;Grace Png.;Niclas Eriksson.;Jeffrey Haessler.;Xiaowei Hu.;Daniela Zanetti.;Thibaud Boutin.;Shih-Jen Hwang.;Eleanor Wheeler.;Maik Pietzner.;Laura M Raffield.;Anette Kalnapenkis.;James E Peters.;Ana Viñuela.;Arthur Gilly.;Sölve Elmståhl.;George Dedoussis.;John R Petrie.;Ozren Polašek.;Lasse Folkersen.;Yan Chen.;Chen Yao.;Urmo Võsa.;Erola Pairo-Castineira.;Sara Clohisey.;Andrew D Bretherick.;Konrad Rawlik.; .; .;Tõnu Esko.;Stefan Enroth.;Åsa Johansson.;Ulf Gyllensten.;Claudia Langenberg.;Daniel Levy.;Caroline Hayward.;Themistocles L Assimes.;Charles Kooperberg.;Ani W Manichaikul.;Agneta Siegbahn.;Lars Wallentin.;Lars Lind.;Eleftheria Zeggini.;Jochen M Schwenk.;Adam S Butterworth.;Karl Michaëlsson.;Yudi Pawitan.;Peter K Joshi.;J Kenneth Baillie.;Anders Mälarstig.;Alexander P Reiner.;James F Wilson.;Xia Shen.
来源: Circulation. 2022年145卷18期1398-1411页
SARS-CoV-2, the causal agent of COVID-19, enters human cells using the ACE2 (angiotensin-converting enzyme 2) protein as a receptor. ACE2 is thus key to the infection and treatment of the coronavirus. ACE2 is highly expressed in the heart and respiratory and gastrointestinal tracts, playing important regulatory roles in the cardiovascular and other biological systems. However, the genetic basis of the ACE2 protein levels is not well understood.
|